Introduction
Anti-ganglioside GM1 IgM antibodies have been reported in 30-50% of patients with multifocal motor neuropathy (MMN) and, less frequently, with other immune neuropathies or motor neuron disease (MND) (van Schaik et al., 1995) . The pathogenic role of these antibodies in MMN is still unclear as well as what causes the disease in MMN GM1 negative patients. It is also unclear how similar antibodies may be associated with and potentially responsible for different diseases (Nobile-Orazio, 2001) . Recently, several reports described the presence of IgG antibodies against complexes of different gangliosides, called anti-ganglioside complexes (GSCs) antibodies, in patients with Guillain-Barré or Fisher syndrome (Kaida et al., 2004 (Kaida et al., , 2006 . In these patients antibodies to GSCs have been detected in approximately 5% of patients not bearing antibodies to the individual gangliosides forming the complexes (positive interaction). At the same time in some patients the mixture of some gangliosides blocked the reactivity to the individual ganglioside forming the GSCs (negative interaction). In these patients reactivity to GSCs was variably related to some clinical features (Kaida et al., 2007 (Kaida et al., , 2008a . Little is known on the presence of anti-GSCs IgM antibodies in MMN or other chronic immunemediated neuropathies.
Material and methods

Patients
We examined 172 patients with MMN or other immune or nonimmune neuropathies and related diseases recruited and tested for anti-nerve antibodies at our Neuropathy Clinics since 2004. All patients had serum collected at the time of other blood tests and they all consented to its use for research. The Internal Review Board of our Institutions approved the study. 
